FOOD AND FASTING PERIODS AS MEDICINE TO PREVENT DISEASE
Professor Leonie Heilbronn
University of Adelaide &
Group Leader Obesity and Metabolism,
South Australian Health and Medical Research Institute (SAHMRI)
Adelaide, South Australia
RESEARCHER PROFILE
Filmed in Adelaide, South Australia | February 2025
Professor Leonie Heilbronn is based at the South Australian Health and Medical Research Institute (SAHMRI), where she leads the Obesity and Metabolism laboratory. Her research is at the interface between basic and clinical science. She is internationally recognised for her work in nutritional modulation in humans and has made major contributions to our current understanding of mechanisms underlying conditions such as insulin resistance, particularly inflammation and lipid metabolism. She has also contributed significantly to current concepts of caloric restriction (CR), intermittent fasting (IF) and time restricted eating (TRE) in humans. She has published more than 110 peer reviewed papers in scientific journals and is an Associate Editor of Obesity, and Obesity Research and Clinical Practice.
Prof. Heilbronn is a translational investigator in obesity and diabetes research. She has a particular interest in understanding how fasting and meal timing alter nutrient signalling pathways to improve health and contributed extensively to current concepts in calorie restriction, intermittent fasting and time restricted eating. She has published more than 140 peer-reviewed manuscripts, and has a current h-index of 44. She is an Associate Editor of Obesity and the European Journal of Endocrinology. She is President of the Australia and New Zealand Obesity Society and an Associate Member of the Australian Academy of Health and Medical Science.
-
Causal genes and pathogenic mechanisms underlying gastrointestinal diseases
Professor D’Amato has more than 25 years research experience in the field of human genetics and complex diseases, with activities most recently geared towards a translational application for therapeutic precision in gastroenterology. His team, the Gastrointestinal Genetics Laboratory, combine leading expertise in genomic, computational and pre-clinical research, and have contributed important breakthroughs linking specific genes and pathogenetic mechanisms to a number of gastrointestinal diseases like inflammatory bowel disease (IBD), microscopic colitis (MC) and irritable bowel syndrome (IBS).
-
Novel immunotherapies in lymphoma
Dr Sean Harrop is a dual-trained haematologist having completed his clinical and laboratory haematology training at the Peter MacCallum Cancer Centre, Royal Melbourne Hospital and St Vincent’s Hospital Melbourne. He is the current clinical haematology fellow (aggressive lymphoma) at Peter MacCallum and a PhD student in the Cancer Immunology Program in the Neeson Lab.
-
Health and economic burden of interstitial lung diseases
Dr Cox’s main research interests focus on respiratory diseases and primarily on the economic burden and economic evaluation of interventions and treatments for their management. She earned her PhD from the University of Tasmania where her doctoral research examined the health and economic burden of idiopathic pulmonary fibrosis (IPF) in Australia, one component of the NHMRC Centre for Research Excellence for Pulmonary Fibrosis, a national project implemented alongside the Australian IPF Registry and the Lung Foundation Australia. This research provided the first epidemiological profile and first costing estimates of the economic burden of the disease in Australia, providing essential evidence for health service reimbursement policies.
